Abstract: Disclosed is a novel physiologically active protein, which is a human granulocyte colony stimulating factor isoform, constructed in order to increase the in vivo lifetime of human granulocyte colony sedtimulating factor. The human granulocyte colony stimulating factor isoform comprises a polypeptide and polyethylene glycol (PEG) bound thereto as a non-protein polymer. A specific site of the polypeptide is selected so that polyethylene can be bound to the site while not adversely affecting the activity of the protein. The amino acid of the site is modified with cysteine and polyethylene glycol is bound to the modified site. A pharmaceutical composition comprising the isoforms, genes encoding the isoforms, and a primer for modifying the amino acid sequence are also disclosed.

Abstract: Disclosed is a novel physiologically active protein, which is a human granulocyte colony stimulating factor isoform, constructed in order to increase the in vivo lifetime of human granulocyte colony sedtimulating factor. The human granulocyte colony stimulating factor isoform comprises a polypeptide and polyethylene glycol (PEG) bound thereto as a non-protein polymer. A specific site of the polypeptide is selected so that polyethylene can be bound to the site while not adversely affecting the activity of the protein. The amino acid of the site is modified with cysteine and polyethylene glycol is bound to the modified site. A pharmaceutical composition comprising the isoforms, genes encoding the isoforms, and a primer for modifying the amino acid sequence are also disclosed.

Abstract: Disclosed are human G-CSF isoforms having a modified amino acid sequence containing a glycosylation sequence Asn-X-Ser/Thr (N-X-S/T) at one or more specific amino acid positions according to the present invention, genes encoding the human G-CSF isoforms, and expression vectors carrying the genes, eukaryotic cells transformed or transfected with the expression vectors. Also, the present invention discloses a method of preparing a glycosylated human G-CSF isoform, comprising the steps of culturing the transformant or transfectant and isolating a glycosylated human G-CSF isoform from the culture supernatant or cell lysates, a human G-CSF isoform prepared by the method, and a pharmaceutical composition comprising the human G-CSF isoform.

Abstract: The present invention relates to an amino acid-modified human interferon alpha isoform having at least one of the Asn-Xaa-Ser/Thr (N-X-S/T) sequence formed at a specific site so that glycosylation takes place at this site and a gene encoding the same, an expression vector comprising the gene, and a method for producing glycosylated human interferon alpha isoform by transforming or transfecting an eukaryotic cell with the expression vector, culturing the transfected or transformed cell and isolating the glycosylated human interferon alpha isoform from the culture, the glycosylated human interferon alpha isoform produced therefrom and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to an amino acid-modified human interferon alpha isoform having at least one of the Asn-Xaa-Ser/Thr (N-X-S/T) sequence formed at a specific site so that glycosylation takes place at this site and a gene encoding the same, an expression vector comprising the gene, and a method for producing glycosylated human interferon alpha isoform by transforming or transfecting an eukaryotic cell with the expression vector, culturing the transfected or transformed cell and isolating the glycosylated human interferon alpha isoform from the culture, the glycosylated human interferon alpha isoform produced therefrom and a pharmaceutical composition comprising the same.

Abstract: Disclosed are human G-CSF isoforms having a modified amino acid sequence containing a glycosylation sequence Asn-X-Ser/Thr (N-X-S/T) at one or more specific amino acid positions according to the present invention, genes encoding the human G-CSF isoforms, and expression vectors carrying the genes, eukaryotic cells transformed or transfected with the expression vectors. Also, the present invention discloses a method of preparing a glycosylated human G-CSF isoform, comprising the steps of culturing the transformant or transfectant and isolating a glycosylated human G-CSF isoform from the culture supernatant or cell lysates, a human G-CSF isoform prepared by the method, and a pharmaceutical composition comprising the human G-CSF isoform.